<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527095</url>
  </required_header>
  <id_info>
    <org_study_id>FDL169-2017-06</org_study_id>
    <nct_id>NCT03527095</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Randomised, Cross Over Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects Following Single Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flatley Discovery Lab LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flatley Discovery Lab LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, cross-over study comprised of 6 periods in healthy subjects.Subjects
      will receive Regimens A, B and C in a randomised crossover manner in the fed state, followed
      by Regimens D, E and F in a randomised crossover manner, in the fasted or fed state, as
      applicable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single centre, randomised, cross-over study comprised of 6 periods in healthy males
      and females.Subjects will receive Regimens A, B and C in a randomised crossover manner in the
      fed state, followed by Regimens D, E and F in a randomised crossover manner, in the fasted or
      fed state, as applicable.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability of FDL169 and its metabolites with different formulations</measure>
    <time_frame>17 weeks</time_frame>
    <description>To determine the relative bioavailability of FDL169 and its metabolites M1 and M3, following different tablet formulations compared to a reference tablet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>17 weeks</time_frame>
    <description>Safety and tolerability of FDL169 and its metabolites M1 and M3 , as determined by the incidence of adverse events (Aes) and serious adverse events (SAE)s.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters, Cmax</measure>
    <time_frame>17 weeks</time_frame>
    <description>The pharmacokinetic parameters of FDL169 and its metabolites M1 and M3 , maximal plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters, Tmax</measure>
    <time_frame>17 weeks</time_frame>
    <description>The pharmacokinetic parameters of FDL169 and its metabolites M1 and M3; maximal concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters, AUC</measure>
    <time_frame>17 weeks</time_frame>
    <description>The pharmacokinetic parameters of FDL169 and its metabolites M1 and M3; area under the plasma concentration curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 200 mg reference tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 200 mg testing tablet 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 200 mg testing tablet 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 200 mg testing tablet 1 or 2 with high fat diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 200 mg testing tablet 1 or 2, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDL169 200 mg testing tablet 1 or 2, with standard diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDL169</intervention_name>
    <description>CFTR corrector</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and non-pregnant, non-lactating female subjects

          -  Aged 18 to 55 years

          -  Body mass index of 18.0 to 32.0 kg/m2

          -  Must agree to the use of an adequate method of contraception

        Exclusion Criteria:

          -  Subjects who have received any IMP in a clinical research study within the previous 3
             months

          -  History of any drug or alcohol abuse in the past 2 years

          -  Current smokers and those who have smoked within the last 12 months.

          -  Alkaline phosphatase, aspartate aminotransferase and/or alanine aminotransferase level
             &gt;1.5 x upper limit of normal at screening

          -  Abnormal renal function at screening

          -  Clinically significant abnormal biochemistry, haematology, coagulation profile or
             urinalysis

          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

          -  History of clinically significant cardiovascular, renal, hepatic, chronic respiratory
             or GI disease, neurological or psychiatric disorder.

          -  Subjects with a history of gall stones or abdominal surgery eg cholecystectomy

          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients

          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug or
             herbal remedy (including known inhibitors or inducers of CYP3A4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Ordonez</last_name>
    <role>Study Chair</role>
    <affiliation>Flatley Discovery Lab</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy O'Toole</last_name>
    <phone>+1 6179043708</phone>
    <email>timothyotoole@flatleydiscoverylab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Robinson</last_name>
      <phone>+44 (0)115 931 5515</phone>
      <email>Anna.Robinson@quotientsciences.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

